Richard -- Little comment on this thread since you elected to add to each of 2000 and 2001 the 500 of TLRK, which to me is a bit of a mystery BT (but then, most of them are <g>). Four consecutive deals (ChemoCentryx, Protherics, Neogenesis and CRL) apparently designed to make their molecular science capability even bigger--CAMD from Protherics, small molecule drug candidates discovery tools, CRL's chemistry discovery platform, etc. TLRK already has a pretty full plate, what with cancer (where MZ cast some aspersion on its anti-tubilin binder), anti-folate; CMV; anti-infection (through TTP subsidiary); PPAR gamma for diabetes, obesity; inflammation and RA; and the Japan Tobacco program. Why the recent acquisition-related focus on additional molecular candidates and processes? In your view, and with the absence of new partner to co-develop one of TLRK's drug discovery programs, does this convey lack of belief in its existing pipe?
Approx. $220 million in cash and equivalents as of 9/30/01; apparently nothing issued yet pursuant to the shelf filed this summer.
Which of the company's programs grabbed your attention the most when you decided to add? Or was it enormous leverage, and serious downside risk. TLRK is old-time, rip-roaring biotech investing? <gg>
(Your description of the founders and their objectives reminds me a bit of CRGN's founder/CEO profile and ambition.)
Interested, of course, to know your thoughts.
tia,
quid |
